Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin

Vaccine

Volumn 26, Issue 40, 2008, Pages 5079-5082

  Boberg, A ^a,b   Gaunitz, S ^c   Brave A ^a,b   Wahren, B ^a,b   Carlin, N ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c SBL Vaccin AB   (Sweden)

Author keywords

CTB; Drug resistance; Fusion protein; HIV; Immunization

Indexed keywords

CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; EPITOPE; GANGLIOSIDE; GANGLIOSIDE RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS 1 PEPTIDE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; PEPTIDE RCTB RT33-41 M41L; RECOMBINANT CHOLERA TOXIN B SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLERA; CONTROLLED STUDY; CROSS REACTION; DOSE TIME EFFECT RELATION; DRUG CONJUGATION; FEMALE; FOLLOW UP; GENE FUSION; GENE MUTATION; GENE SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN PROTEIN INTERACTION; WILD TYPE;

AIDS VACCINES; ANIMALS; CHOLERA TOXIN; EPITOPES, T-LYMPHOCYTE; HIV ANTIBODIES; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; IMMUNIZATION; IMMUNOLOGIC MEMORY; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; VACCINES, CONJUGATE;

EID: 50849138163     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.096     Document Type: Article

References (18)

1. Turner D., and Wainberg M.A. HIV transmission and primary drug resistance. AIDS Rev 8 1 (2006) 17-23
2. Sommerfelt M.A., Nyhus J., and Sorensen B. Novel peptide-based HIV-1 immunotherapy. Expert Opin Biol Ther 4 3 (2004) 349-361
3. Okazaki T., Terabe M., Catanzaro A.T., Pendleton C.D., Yarchoan R., and Berzofsky J.A. Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice. J Virol 80 21 (2006) 10645-10651
4. Boberg A., Sjostrand D., Rollman E., Hinkula J., Zuber B., and Wahren B. Immunological cross-reactivity against a drug mutated HIV-1 protease epitope after DNA multi-CTL epitope construct immunization. Vaccine 24 21 (2006) 4527-4530
5. Hinkula J. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity. Expert Rev Vac 6 2 (2007) 203-212
6. Holmgren J., Adamsson J., Anjuere F., Clemens J., Czerkinsky C., Eriksson K., et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 97 2 (2005) 181-188
7. Holmgren J., and Czerkinsky C. Mucosal immunity and vaccines. Nat Med 11 4 Suppl (2005) S45-S53
8. Firat H., Tourdot S., Ureta-Vidal A., Scardino A., Suhrbier A., Buseyne F., et al. Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic H-2 class I KO mice. Eur J Immunol 31 10 (2001) 3064-3074
9. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., and Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8 (+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185 12 (1997) 2043-2051
10. Pett M.A. Nonparametric Statistics for Health Care Research (1997), SAGE Publications, Inc., Thousand Oaks, CA
11. Costagliola D., Descamps D., Assoumou L., Morand-Joubert L., Marcelin A.G., Brodard V., et al. Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr 46 1 (2007) 12-18
12. Palma A.C., Araujo F., Duque V., Borges F., Paixao M.T., and Camacho R. Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal. Infect Genet Evol 7 3 (2007) 391-398
13. Tang J.W., and Pillay D. Transmission of HIV-1 drug resistance. J Clin Virol 30 1 (2004) 1-10
14. Johnson V.A., Brun-Vezinet F., Clotet B., Kuritzkes D.R., Pillay D., Schapiro J.M., et al. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med 14 3 (2006) 125-130
15. Holmgren J., Lycke N., and Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 11 12 (1993) 1179-1184
16. Oien N.L., Brideau R.J., Walsh E.E., and Wathen M.W. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Vaccine 12 8 (1994) 731-735
17. Tamura S., Samegai Y., Kurata H., Nagamine T., Aizawa C., and Kurata T. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 6 5 (1988) 409-413
18. Boberg A., and Isaguliants M. Vaccination against drug resistance in HIV infection. Expert Rev Vaccines 7 1 (2008) 131-145